Clinical trial
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in…
NCT00443573 · ARCA Biopharma, Inc., Industry · Suspended
Key facts
| NCT number | NCT00443573 |
|---|---|
| Title | Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer |
| Official title | Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2 |
| Lead sponsor | ARCA Biopharma, Inc., Industry |
| Status | Suspended |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colon Cancer |
| Intervention type | Drug |
| Interventions | recombinant nematode anticoagulant protein c2 (rNAPc2) |
| Enrollment | 100 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2007 |
| First posted | Mar 6, 2007 |
| Last update posted | May 7, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: